DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 8194260. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is in a pivotal Phase 3 trial for the treatment of mRCC, and the company plans to have data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid- 2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
CONTACT: Jeffrey Abbey President & Chief Executive Officer Argos Therapeutics firstname.lastname@example.org (919) 287-6308 Media: Andrea Coan Berry & Company Public Relations email@example.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan firstname.lastname@example.org (212) 213-0006Source:Argos Therapeutics, Inc.